Sebastian Szmit: Advances in Managing Cancer-Associated Thromboembolism
OncoDaily shared on LinkedIn:
”Dr. Sebastian Szmit Highlights Advances in Managing Cancer-Associated Thromboembolism at GCOS 2025
Dr. Sebastian Szmit, from the Institute of Hematology and Transfusion Medicine and the Center of Postgraduate Medical Education in Warsaw, delivered an engaging talk on cancer-associated thromboembolism. He discussed premature mortality linked to VTE in cancer patients and reviewed ESC guideline–based anticoagulation options, comparing DOACs (apixaban, edoxaban, rivaroxaban) with low-molecular-weight heparin (LMWH). He emphasized that while DOACs are effective, LMWH remains preferred in gastrointestinal cancers due to higher bleeding risks.
Dr. Szmit also presented findings from the APICAT study, which showed that a reduced dose of apixaban can maintain efficacy while lowering bleeding risk during extended anticoagulation. He highlighted challenges such as drug interactions, thrombocytopenia, and the need for improved primary prophylaxis strategies tailored to cancer therapy.”
Stay informed with Hemostasis Today.
-
Nov 8, 2025, 05:31Phenotyping of Human Platelets by Daisie Yates
-
Nov 8, 2025, 04:35Inaugural Women In Hematology US Focus Meeting 2025 Officially Commenced
-
Nov 8, 2025, 01:40Mikhail Fominykh: What I Read This Week
-
Nov 8, 2025, 01:40Shubham Khandve: Cell and Gene Therapy is No Longer the Future
-
Nov 8, 2025, 01:39World Federation of Hemophilia: Hemophilia Care is Evolving
-
Nov 8, 2025, 01:38Muhammad Awidi – Choking Growth One Puff at a Time: How Tobacco is Strangling Jordan’s Economy
-
Nov 8, 2025, 01:38Abdul Mannan Inside the Diagnostic Maze of Atypical CML
-
Nov 8, 2025, 01:37Steven Murphy Discusses Peptides in Orthobiologic Medicine at AMSKU 2025
-
Nov 8, 2025, 01:37Cellfie of the Day: Classic Gaucher Cells Under the Microscope